Recommendation based on the findings from the Phase 3 ASTRO study in ulcerative colitis.1,2,3 Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and intravenous induction options in ulcerative colitis, providing flexibility and simplicity for patients and physicians.1,4

Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive CHMP opinion is supported by results from the Phase 3 Vivacity-MG3 and Phase 2/3 Vibrance-mg studies over 24 weeks, which demonstrated a sustained reduction in immunoglobulin G (IgG) levels, one of the root causes of autoantibody diseases

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies.1 Icotrokinra also showed sustained skin clearance and favourable safety profile, relative to placebo, in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study.2 Robust findings continue to demonstrate the potential of icotrokinra to transform the treatment paradigm for treating patients with moderate-to-severe plaque psoriasis.1,2

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented data package includes head-to-head superiority comparisons versus deucravacitinib, adolescent data and evaluation of difficult to treat skin sites.2,3,4,5,6 Submission underscores that icotrokinra has the potential to offer moderate-to-severe plaque psoriasis patients the combination of complete skin clearance and a favourable safety profile, relative to comparators, with the simplicity of a once-daily tablet.2,3,4,5,6

New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1

Guselkumab 100 mg/1 mL solution for injection in pre-filled pen (PushPen) expands administration options and continuity of care,1,2 offering a spring-loaded, fully automated injection with built-in safety mechanism,2 helping to reduce needle accidents and consequently administration anxiety.2,3